worx11's oncology [19 articles] Export

Recent papers added to worx11's library classified by the tag oncology. You can also see everyone's oncology.

	Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials. [My Copy] Cancer, Vol. 110, No. 7. (20 August 2007), pp. 1621-1628. by David R R. Buchanan, Ann M M. O'mara, Joseph W W. Kelaghan, Maria Sgambati, Worta McCaskill-Stevens, Lori Minasian posted to bm oncology quality quality_of_life by worx11 on 2007-09-21 17:19:50 as along with 1 person and 1 group suizan XROWXR
	Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. [My Copy] Clin Ther, Vol. 27, No. 8. (August 2005), pp. 1295-1310. by E. De Cock, J. Hutton, P. Canney, et al.J. J. Body, P. Barrett-Lee, M. P. Neary, G. Lewis posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:23:29 as along with 1 group XROWXR
	Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. [My Copy] Support Care Cancer, Vol. 13, No. 12. (December 2005), pp. 975-986. by E. De Cock, J. Hutton, P. Canney, et al.J. J. Body, P. Barrett-Lee, M. P. Neary, G. Lewis posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:21:31 as along with 1 group XROWXR
	The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy. [My Copy] Am J Health Syst Pharm, Vol. 64, No. 15 Suppl 10. (1 August 2007) by C. Downs posted to bm medicare medicare_part_d oncology by worx11 on 2007-09-20 20:17:29 as along with 1 group XROWXR
	Formulary issues at a pediatric hospital: experience at Children's National Medical Center. [My Copy] Hosp Formul, Vol. 26, No. 6. (June 1991), pp. 500-510. by G. J. Cohen, S. J. Allen posted to bm formulary oncology outcomes by worx11 on 2007-09-20 20:14:23 as along with 1 group XROWXR
	Many new cancer drugs in the United Kingdom are facing negative NICE rulings. [My Copy] J Clin Oncol, Vol. 25, No. 18. (20 June 2007) by E. Low, posted to bm oncology outcomes by worx11 on 2007-09-20 20:11:50 as along with 1 group XROWXR
	European perspective on the costs and cost-effectiveness of cancer therapies. [My Copy] J Clin Oncol, Vol. 25, No. 2. (10 January 2007), pp. 191-195. by M. F. Drummond, A. R. Mason posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:08:00 as along with 1 group XROWXR
	Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. [My Copy] Br J Cancer, Vol. 89, No. 4. (18 August 2003), pp. 634-640. by A. Gordois, P. Scuffham, E. Warren, S. Ward posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:30:11 as along with 1 group XROWXR
	Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. [My Copy] Health Technol Assess, Vol. 8, No. 28. (July 2004) by K. Dalziel, A. Round, K. Stein, R. Garside, A. Price posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:27:43 as along with 1 group XROWXR
	Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. [My Copy] Pharmacoeconomics, Vol. 23, No. 5. (2005), pp. 515-526. by K. Dalziel, A. Round, R. Garside, K. Stein posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:27:07 as along with 1 group XROWXR
	Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. [My Copy] Clin Ther, Vol. 26, No. 11. (November 2004), pp. 1924-1933. by E. Warren, S. Ward, A. Gordois, P. Scuffham posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:25:17 as along with 1 group XROWXR
	Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. [My Copy] Clin Ther, Vol. 26, No. 9. (September 2004), pp. 1546-1561. by M. Marchetti, M. Caruggi, G. Colombo posted to bm budget_impact cost-utility oncology outcomes by worx11 on 2007-09-20 19:23:02 as along with 1 group XROWXR
	Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. [My Copy] Clin Drug Investig, Vol. 27, No. 2. (2007), pp. 85-93. by D. M. Huse, M. von Mehren, G. Lenhart, et al.H. Joensuu, C. Blanke, W. Feng, S. Finkelstein, G. Demetri posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:21:12 as along with 1 person and 1 group Terkko XROWXR
	Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. [My Copy] Clin Breast Cancer, Vol. 7, No. 8. (June 2007), pp. 608-618. by T. E. Delea, J. Karnon, O. Sofrygin, S. K. Thomas, N. L. Papo, V. Barghout posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:18:02 as along with 1 group XROWXR
	Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. [My Copy] Pharmacoeconomics, Vol. 24, No. 3. (2006), pp. 237-250. by J. Karnon, T. Delea, S. R. Johnston, et al.R. Smith, J. Brandman, J. Sung, P. E. Goss posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:16:06 as along with 1 group XROWXR
	Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. [My Copy] Am J Clin Oncol, Vol. 26, No. 3. (June 2003), pp. 289-296. by G. Dranitsaris, S. Verma, M. Trudeau posted to bm cost-utility oncology by worx11 on 2007-09-20 19:15:12 as along with 1 group XROWXR
	Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. [My Copy] Breast, Vol. 16, No. 3. (June 2007), pp. 252-261. by C. Skedgel, D. Rayson, R. Dewar, T. Younis posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:02:57 as along with 1 group XROWXR
	Reimbursement for cancer treatment: coverage of off-label drug indications. [My Copy] J Clin Oncol, Vol. 24, No. 19. (1 July 2006), pp. 3206-3208. by posted to bm oncology by worx11 on 2007-09-20 18:57:10 as along with 1 group XROWXR
	Cost considerations in the management of cancer in the older patient. [My Copy] Oncology (Williston Park), Vol. 21, No. 7. (June 2007) by J. M. McKoy, K. A. Fitzner, B. J. Edwards, et al.M. Alkhatib, C. C. Tigue, N. J. Nonzee, C. R. Bolden, C. L. Bennett posted to bm oncology outcomes by worx11 on 2007-09-20 18:54:02 as along with 1 group XROWXR

Note: You may cite this page as: http://www.citeulike.org/user/worx11/tag/oncology

diabetes	390
me	337
bm	247
lg	207
sm_dossier	206
senior_care_research	169
hiv	164
lipodystrophy	151
economic	70
medicare	70
as	67
medicare_part_d	59
glargine	52
long_term_care	51
cost-effectiveness	48
skilled_nursing_facility	47
snf	46
nursing_facility	44
nursing_home	42
jmcp_manuscript	39
cmrf	37
home_healthcare	31
assisted_living	27
depression	24
zt	21
benefit_design	20
copd	20
oncology	19
caregiving	18
smoking_cessation	18
outcomes	16
type_1_diabetes	16
mm	15
pediatrics	15
pa_research	14
hospital	13
medication_therapy_management	13
quality	13
medicaid	11
mtm	9
ac	6
chemoprevention	6
serm	6
ahrq	5
cost-utility	5
cr_supplement	5
statin	5
asthma	3
pharmacist	3
quality_of_life	3
regulatory	3
standard_of_care	3
derm	2
formulary	2
budget_impact	1
consumers	1
cost_benefit	1
disease_management	1
drug_trends	1
evidence_based	1
exenatide	1
generic	1
osteoporosis	1
pa_researcj	1
pipeline	1
rehabilitation	1
senior_care_research_home_healthcare	1

worx11's oncology [19 articles] Export

worx11's tags